文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

非融合二极管激光全视网膜光凝治疗玻璃体腔注射贝伐珠单抗后侵袭性后部早产儿视网膜病变的结局

OUTCOMES OF NONCONFLUENT DIODE LASER PANRETINAL PHOTOCOAGULATION FOR AGGRESSIVE POSTERIOR RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB.
PubMed 文献 · Retina · 2021-01-01

回顾性连续病例系列研究评估了31例侵袭性后部早产儿视网膜病变婴儿(61眼)在玻璃体腔注射贝伐珠单抗后接受改良间接二极管激光全视网膜光凝的安全性和有效性。平均随访3.9年,末次随访时无患者出现激光后复发、视网膜脱离、前节缺血或其他激光并发症。结论提示该非融合全视网膜光凝方案可能安全有效。

要点

  • 玻璃体腔注射贝伐珠单抗后行非融合全视网膜光凝,末次随访未观察到复发或视网膜脱离。
  • 研究纳入61眼,平均出生体重661.5克,平均随访3.9年,无前节缺血等激光并发症。
  • 该方案的安全有效性需更大样本前瞻性研究进一步验证。

核心结论

  • 对于接受玻璃体腔注射贝伐珠单抗的侵袭性后部早产儿视网膜病变婴儿,非融合全视网膜光凝可能是安全有效的。

研究设计与样本

  • 共61眼(31例早产儿),平均胎龄24±2.2周(范围22-27周),平均出生体重661.5±167.1克(范围340.0-930.5克),平均随访3.9±1.3年(范围1.3-5.4年)。

主要发现

  • 末次随访时,无患者出现激光后复发、视网膜脱离、前节缺血或其他激光并发症。

临床怎么用

  • 对玻璃体腔注射贝伐珠单抗后出现病变复发或血管化不完全的侵袭性后部早产儿视网膜病变婴儿,可考虑采用非融合全视网膜光凝,但需注意个体化评估。

局限性

  • 回顾性研究设计,非随机对照,样本来自单一中心且由单一有经验的早产儿视网膜病变专家治疗,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the safety and efficacy of less dense panretinal photocoagulation after intravitreal bevacizumab in aggressive posterior retinopathy of prematurity infants. METHODS: Retrospective consecutive case series of premature infants diagnosed with aggressive posterior retinopathy of prematurity between August 2012 and November 2015 who received intravitreal bevacizumab with subsequent modified indirect diode laser panretinal photocoagulation for reactivation or incomplete vascularization. Main outcome measures included postprocedural reactivation, retinal detachments, or anterior segment ischemia. RESULTS: Sixty-one eyes of 31 premature infants were identified. The average gestational age was 24 ± 2.2 weeks (range 22-27), and the average birth weight was 661.5 ± 167.1 g (range 340.0-930.5 g). The average follow-up was 3.9 ± 1.3 years (range 1.3-5.4 years). At the last follow-up, no patient had experienced postlaser reactivation, retinal detachments, anterior segment ischemia, or other laser complications. CONCLUSION: This study suggests that nonconfluent panretinal photocoagulation for aggressive posterior retinopathy of prematurity infants who have received intravitreal bevacizumab may be safe and effective. This study's strengths include a sizeable sample size, long-term follow-up of nearly 4 years, and consistency in treatment among patients by a single, experienced retinopathy of prematurity specialist.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Mammo DA, Rubino SM, Quiram PA, et al. OUTCOMES OF NONCONFLUENT DIODE LASER PANRETINAL PHOTOCOAGULATION FOR AGGRESSIVE POSTERIOR RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB. Retina. 2021. PMID: 32796444. doi:10.1097/IAE.0000000000002943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。